Journal of Cardiac Failure
Volume 16, Issue 2 , Pages 128-134 , February 2010

Baseline Plasma NT-proBNP and Clinical Characteristics: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Trial

  • Robert S. Mckelvie, MD, PhD

      Affiliations

    • McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    • Corresponding Author InformationReprint requests: Dr. Robert S. McKelvie, Hamilton Health Sciences Corporation – General Site, 237 Barton Street East, Hamilton, Ontario, Canada, L8L 2X2; Tel: (905) 572-7155, Fax: (905) 577-1480.
    • ,
  • Michel Komajda, MD

      Affiliations

    • Pitie-Salpetriere Hospital, Paris, France
    • ,
  • John Mcmurray, MD

      Affiliations

    • University of Glasgow, Glasgow, United Kingdom
    • ,
  • Michael Zile, MD

      Affiliations

    • Medical University of South Carolina and VAMC, Charleston, SC
    • ,
  • Agata Ptaszynska, MD

      Affiliations

    • Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, NJ
    • ,
  • Mark Donovan, PhD

      Affiliations

    • Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, NJ
    • ,
  • Peter Carson, MD

      Affiliations

    • Georgetown University and VAMC, Washington, DC
    • ,
  • Barry M. Massie, MD

      Affiliations

    • University of California San Francisco and VAMC, San Francisco, CA
    • ,
  • I-Preserve Investigators

Received 28 August 2008 ,Revised 27 July 2009 ,Accepted 24 September 2009.

References 

  1. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komjada M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (Update 2005). The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:1115–1140
  2. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiographic Associations of the European Society of Cardiology. Euro Heart J. 2007;28:2539–2550
  3. Yoshimura M, Yasue H, Okumura K, Ogawa N, Jougasaki M, Mukoyama M, et al. Different secretion pattern of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation. 1993;87:464–469
  4. Nakagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide as an “emergency” cardiac hormone against ventricular overload. J Clin Invest. 1995;96:1280–1287
  5. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195–203
  6. Clerico A, Iervasi G, Del Chicca MG, Emdin M, Maffei S, Nannipieri M, et al. Circulating levels of cardiac Natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest. 1998;21:170–179
  7. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–167
  8. McDonagh TA, Holmer S, Raymond I, Luchner A, Hildebrant P, Dargie HJ. NT proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. Eur J Heart Failure. 2004;6:269–273
  9. Sanderson JE. BNP or echocardiography for monitoring heart failure?. Eur Heart J. 2004;25:1763–1764
  10. Bayes-Genis A, Santalo-Bel M, Zapico-Muniz E, Lopez L, Cotes C, Bellido J, et al. N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnea and ventricular dysfunction. Eur J Heart Fail. 2004;6:301–308
  11. Kirk V, Bay M, Parner J, Krogsgaard K, Herzog TM, Boesgaard S, et al N-terminal proBNP and mortality in hospitalized patients with heart failure and preserved vs reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF). Eur J Heart Fail. 2004;6:335–341
  12. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction. Comparison with Doppler velocity recording. Circulation. 2002;105:595–601
  13. TschÖpe C, Kašner M, Westermann D, Gaub R, Poller WC, Schultheiss HP. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J. 2005;26:2277–2284
  14. Valle R, Aspromonte N, Feola M, Milli M, Canali C, Giovinazzo P, et al. B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function. J Card Fail. 2005;11:498–503
  15. Carson P, Massie BM, McKelvie R, McMurray J, Komajda M, Zile M, et al. The Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) Trial: rationale and design. J Card Failure. 2005;11:576–585
  16. Levey AS, Bosch JP, Lewis JB. Greene t, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Int Med. 1999;130:461–470
  17. Lenzen MJ, Scholte op Reimer WJM, Boersma E, Vantrimpont PJ, Follath F, Swedberg K, et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J. 2004;25:1214–1220
  18. Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis. 2005;47:320–332
  19. Costello-Boerrigter LC, Boerrigter G, Redfield MM, Rodeheffer RJ, Urban LH, Mahoney DW, et al. Amino-terminal Pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community. Determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2006;47:345–353
  20. Abhayaratna WP, Marwick TH, Becker NG, Jeffrey IM, McGill DA, Smith WT. population-based detection of systolic and diastolic dysfunction with amino-terminal pro-B-type natriuretic peptide. Am Heart J. 2006;152:941–948
  21. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338–2345
  22. Dong S-J, de las Fuentes L, de las Fuentes L, Brown AL, Waggoner AD, Ewald GA, et al. N-terminal pro B-type natriuretic peptide levels: correlation with echocardiographically determined left ventricular diastolic function in an ambulatory cohort. J Am Soc Echocardiogr. 2006;19:1017–1025
  23. Cleland JGF, Tahlor J, Tendera M. Prognosis in heart failure with a normal ejection fraction. N Engl J Med. 2007;357:829–830
  24. Kjekshus J, Apetrei E, Barrios V, Boham M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248–2261
  25. Cleland JGF, Daubert J-C, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac desynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–1549
  26. Valle R, Aspromonte N, Barro S, Canali C, Carbonieri E, Ceci V, et al. The NT proBNP assay identifies very elderly nursing home residents suffering form preclinical heart failure. Eur J Heart Fail. 2005;7:542–551
  27. Conraads VM, Beckers P, Vaes J, Martin M, Van Hoof V, De Maeyer C, et al. Combined endurance/resistance training reduces NT-proBNP levels in patients with chronic heart failure. Eur Heart J. 2004;25:1797–1805
  28. Januzzi JL, van Kimmendade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo Bel M, et al. Nt-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. The International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27:330–337
  29. O'Donoghue M, Chen A, Baggish AL, Anwaruddin S, Krauser DG, Tung R, et al. The effects of ejection fraction on N terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Card Fail. 2005;11:S9–14
  30. Watanabe S, Shite J, Takaoka H, Shinke T, Imuro Y, Ozawa T, et al. Myocardial stiffness is an important determinant of the plasma brain natriuretic peptide concentration in patients with both diastolic and systolic heart failure. Eur Heart J. 2006;27:832–838
  31. Iwanaga Y, Nishi I, Furuichi S, Noguchi T, Sase K, Kihara Y, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure. Comparison between systolic and diastolic heart failure. J Am Coll Cardiol. 2006;47:742–748
  32. Johnston N, Jernberg T, Lindahl B, Lindback J, Stridsberg M, Larsson A, et al. Biochemical indicators of cardiac and renal function in a healthy elderly population. Clin Biochem. 2004;37:210–216
  33. Alehagen U, Svensson E, Dahlstrom U. Natriuretic peptide biomarkers as information indicators in elderly patients with possible heart failure followed over six years: a head-to-head comparison of four cardiac natriuretic peptides. J Cardiac Fail. 2007;13:452–461
  34. Ingle L, Cleland JGF, Clark AL. Perception of symptoms is out of proportion to cardiac pathology in patients with “diastolic heart failure”. Heart. 2008;94:748–753
  35. Grewal J, McKelvie RS, Persson H, Tait P, Carlsson J, Swedberg K, et al. Usefulness of N terminal pro-brain natriuretic peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. Am J Cardiol. 2008;102:733–737

 All decisions regarding this manuscript were made by a guest editor.

 All of the authors have disclosures related to the sponsors of the I-Preserve Trial (Bristol Myers Squibb and Sanofi-Aventis): Consulting fees: R.S.M., M.K., J.M., M.Z., P.C., B.M.M.; Research support: R.S.M., M.Z., B.M.M.; Speaking honoraria: R.S.M., M.K., J.M., M.Z., P.C., B.M.M.; Employee of Bristol Myers Squibb: A.P., M.D.

PII: S1071-9164(09)01091-4

doi: 10.1016/j.cardfail.2009.09.007

Journal of Cardiac Failure
Volume 16, Issue 2 , Pages 128-134 , February 2010

Article Tools